Star Therapeutics raises $200M after Vega and Electra exits
- Star Therapeutics announced a $200M private financing co-led by OrbiMed and Janus Henderson Investors, with several existing specialist investors participating.
- It follows the sale of subsidiary Vega Therapeutics to Incyte (up to $2B, July 2026) and the public listing of spinout Electra.
- Proceeds are meant to move preclinical hematology and immunology biologics toward the clinic and add new programs.
💡 Points
Two exits in one year, a Vega sale to Incyte worth up to $2B plus an Electra IPO, make Star look less like a single-asset biotech and more like a repeatable company-creation engine. The $200M round is investors paying for that process, not a lead molecule. The risk is that preclinical hematology and immunology biologics are still unproven, and the summary gives no program detail.
Star Therapeutics gets $200M to try repeating its Vega, Electra successes ↗